Table 1.
Baseline characteristics
| Parameter | All patients | Nintedanib | Pirfenidone | No treatment | P-values |
|---|---|---|---|---|---|
| N (%) | 178 | 62 (34.8%) | 80 (44.9%) | 36 (20.2%) | |
| Age, mean (SD) | 73.80 (7.53) | 72.16 (7.15) | 73.66 (6.87) | 76.92 (8.74) | 0.0097 |
| Men, n (%) | 136 (76.4%) | 47 (75.8%) | 62 (77.5%) | 27 (75.0%) | 0.95 |
| BMI, mean (SD) | 27.31 (4.51) | 27.62 (4.62) | 27.57 (4.16) | 26.16 (5.02) | 0.24 |
| FVC (L), mean(SD) | 3.04 (0.86) | 3.05 (0.91) | 3.08 (0.83) | 2.94 (0.88) | 0.7 |
| FVC (% pred), mean(SD) | 89.51 (19.52) | 88.48 (19.57) | 90.09 (18.71) | 90.00 (21.65) | 0.878 |
| DLCO (% pred), mean(SD) | 52.85 (13.25) | 53.81 (12.68) | 52.63 (13.13) | 51.58 (14.80) | 0.725 |
| Change in FVC % pred. from baseline to 12 months, mean (SD) | 0.13 (10.16) | 0.20 (9.92) | 0.06 (10.44) | 0.15 (10.41) | 0.997 |
| Change in DLCO % pred. from baseline to 12 months, mean (SD) | − 5.03 (7.98) | − 4.70 (6.83) | − 5.37 (9.10) | − 4.85 (7.34) | 0.9 |
| 6MWT (meters), mean (SD) | 442.61 (105.58) | 475.92 (95.20) | 436.09 (106.85) | 390.97 (101.61) | 0.0009 |
| Smoking status, n (%) | 0.039 | ||||
| Never | 46 (25.8%) | 10 (16.1%) | 25 (31.2%) | 11 (30.6%) | |
| Active | 11 (6.2%) | 1 (1.6%) | 6 (7.5%) | 4 (11.1%) | |
| Former | 121 (68.0%) | 51 (82.3%) | 49 (61.2%) | 21 (58.3%) | |
| GAP index, n (%) | 0.08 | ||||
| I | 88 (49.7%) | 34 (54.8%) | 36 (45.0%) | 18 (51.4%) | |
| II | 82 (46.3%) | 27 (43.5%) | 42 (52.5%) | 13 (37.1%) | |
| III | 7 (4.0%) | 1 (1.6%) | 2 (2.5%) | 4 (11.4%) | |
| Progression at 12 months, n (%) | 84 (47.2%) | 27 (43.5%) | 38 (47.5%) | 19 (52.8%) | 0.67 |
SD standard deviation, BMI Body Mass Index, FVC forced vital capacity, DLCO diffusion capacity for carbon monoxide, 6MWT six-minute walk test, GAP index Gender-Age-Physiology index, Disease progression was defined as an absolute decline in the percentage of predicted FVC ≥ 5% points and/or an absolute decline in the percentage of predicted DLCO ≥ 10% points and/or all-cause mortality within 12 months